Santo Domingo.- The General Directorate of Medicines, Food, and Health Products (DIGEMAPS) has announced the withdrawal of the Vitafer-L dietary supplement from the market after discovering the presence of tadalafil, an undeclared substance posing health risks to consumers.
The issue was identified following a field investigation and analysis of product samples at DIGEMAPS’ Human Consumption Product Evaluation Laboratory (LEPCH). It was confirmed that Vitafer-L contained tadalafil, a medication typically used to treat erectile dysfunction. This substance belongs to the class of phosphodiesterase type 5 (PDE-5) inhibitors, which can lead to serious health complications when consumed by individuals with certain medical conditions.
As a preventive measure, DIGEMAPS conducted operations across the country on Wednesday, seizing several units of the product.
Manufactured by Natural Medy SAS in Colombia and distributed in the Dominican Republic by Alcavida SRI, Vitafer-L is sold in various doses (10 ml, 20 ml, and 500 ml). The product’s label fails to warn consumers about the presence of tadalafil, which poses serious risks, particularly for individuals with conditions such as heart disease, low blood pressure, stroke history, and liver failure.
DIGEMAPS has urged the public to avoid using Vitafer-L and report its availability in stores. The agency remains committed to ensuring product safety and will continue intensifying operations to remove unsafe products from the market.
